---
title: Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin
  Lymphoma
date: '2023-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37958391/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231114170859&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer
  cases globally. Despite high cure rates with standard treatment, approximately 15%
  of patients still experience relapsed or refractory (RR) disease, and many of these
  eventually die from lymphoma-related causes. Exciting new targeted agents such as
  anti-PD-1 agents and brentuximab vedotin have changed the therapeutic paradigm beyond
  chemotherapy and radiotherapy alone. Advances in understanding of the molecular
  biology ...
disable_comments: true
---
Classical Hodgkin lymphoma (cHL) accounts for 0.4% of all new cancer cases globally. Despite high cure rates with standard treatment, approximately 15% of patients still experience relapsed or refractory (RR) disease, and many of these eventually die from lymphoma-related causes. Exciting new targeted agents such as anti-PD-1 agents and brentuximab vedotin have changed the therapeutic paradigm beyond chemotherapy and radiotherapy alone. Advances in understanding of the molecular biology ...